Вы искали: fondaparinuxgruppen (Датский - Английский)

den mortalitetsgevinst, der blev observeret i fondaparinuxgruppen blev
the mortality benefit shown in the fondaparinux group was maintained until the end of follow-up at day 180. lo in patients who were revascularised with a thrombolytic, fondaparinux significantly reduced the incidence of death/ re-mi at day 30 from 13.6% for the control group to 10.9% (hazard ratio 0.79, no

i fondaparinuxgruppen forekom det primære sammensatte endpoint blandt
of the patients in the fondaparinux group, 5.8% experienced an event by day 9 compared to 5.7% for enoxaparin-treated patients (hazard ratio 1.01, du

den mortalitetsgevinst, der blev observeret i fondaparinuxgruppen blev opretholdt til slutningen af opfølgningsperioden ved dag 180.
the mortality benefit shown in the fondaparinux group was maintained until the end of follow-up at day 180.

den mortalitetsgevinst, der blev observeret i fondaparinuxgruppen blevet opretholdt til slutningen af opfølgningsperioden ved dag 180.
the mortality benefit shown in the fondaparinux group was maintained until the end of follow-up at day 180. lo in patients who were revascularised with a thrombolytic, fondaparinux significantly reduced the incidence of death/re-mi at day 30 from 13.6% for the control group to 10.9% (hazard ratio 0.79, no95%ci, 0.68; 0.93, p = 0.003) .

der blev observeret større blødninger hos 3,4 % af patienterne i fondaparinuxgruppen over for hos 2,4
major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.

der blev observeret større blødninger hos 3,4 % af patienterne i fondaparinuxgruppen og 2,4 % i dalteparingruppen.
major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.

der blev observeret større blødninger hos 3,4 % af patienterne i fondaparinuxgruppen over for 2,4 % i dalteparingruppen.
major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.

der blev observeret større blødninger hos 3, 4% af patienterne i fondaparinuxgruppen over for hos 2, 4% i dalteparingruppen. m
major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.

forekomsten af symptomatisk dvt var den samme i de behandlede grupper, nemlig 6 patienter (0, 4%) i fondaparinuxgruppen over for 5 patienter ikk
the incidence of symptomatic dvt was similar between18 treatment groups:

mortalitetsraten var lav og ens mellem behandlingsgrupperne med 2 (0,1 %) dødsfald i fondaparinuxgruppen versus 1 (0,1 %) dødsfald i placebogruppen.
the mortality rates were low and similar between the treatments groups with 2 (0.1%) deaths in the fondaparinux group versus 1 (0.1%) death in the placebo group.

i den store subgruppe af patienter, som gennemgik cancerkirurgi (69 % af patienterne), var forekomsten af vte 4,7 % i fondaparinuxgruppen mod 7,7 % i dalteparingruppen.
in the large subgroup of patients undergoing cancer surgery (69% of the patient population), the vte rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.